Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma

Allergic asthma rates have increased steadily in developed countries, arguing for an environmental aetiology. To assess the influence of gut microbiota on experimental murine allergic asthma, we treated neonatal mice with clinical doses of two widely used antibiotics—streptomycin and vancomycin—and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO reports 2012-05, Vol.13 (5), p.440-447
Hauptverfasser: Russell, Shannon L, Gold, Matthew J, Hartmann, Martin, Willing, Benjamin P, Thorson, Lisa, Wlodarska, Marta, Gill, Navkiran, Blanchet, Marie-Renée, Mohn, William W, McNagny, Kelly M, Finlay, Brett B
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Allergic asthma rates have increased steadily in developed countries, arguing for an environmental aetiology. To assess the influence of gut microbiota on experimental murine allergic asthma, we treated neonatal mice with clinical doses of two widely used antibiotics—streptomycin and vancomycin—and evaluated resulting shifts in resident flora and subsequent susceptibility to allergic asthma. Streptomycin treatment had little effect on the microbiota and on disease, whereas vancomycin reduced microbial diversity, shifted the composition of the bacterial population and enhanced disease severity. Neither antibiotic had a significant effect when administered to adult mice. Consistent with the ‘hygiene hypothesis’, our data support a neonatal, microbiota‐driven, specific increase in susceptibility to experimental murine allergic asthma. Allergic asthma rates are increasing in developed countries, arguing for an environmental aetiology. Profound changes in gut microbiota are reported in response to treatment in early life with the widely used antibiotic vancomycin, influencing asthma susceptibility.
ISSN:1469-221X
1469-3178
DOI:10.1038/embor.2012.32